ClinicalTrials.gg
Active, not recruitingNCT05641974Updated Nov 18, 2026

Effect of Helpers Program On-line Training on Smoking Relapse and Social Networks

An interventional study of Helpers Stay Quit Training in Smoking and Cigarette Smoking, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionCigarette SmokingRegistry: SmokingReclassifiedWhy we changed it
Registry
Smoking — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cigarette Smoking
Why
  1. The study's listed conditions name Cigarette Smoking, a narrower term within Smoking.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
940
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.

Enrollment
24th of 340
940 · median 96
Started
2022
with 30 others
No phase
226 of 371
41 open now
Primary completion
2026-12
later than 14 of 74 live
Registered
286th of 371
by date

Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 24th largest by enrollment of the 340 interventional ones that give a count, is one of 31 that started in 2022, is one of 226 with no phase, reaches primary completion later than 14 of the 74 other live ones, and was the 286th registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 371 studies in Cigarette Smoking with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of the Helpers Stay Quit training on abstinence over time of newly abstinent smokers, and on the interactions they have with their personal network related to smoking and smoking cessation.

Read the detailed description

Despite major gains in smoking cessation treatment, over half of recently quit smokers will relapse within the first year. To date, relapse prevention interventions have focused on the newly abstinent smoker ("abstainer"), and not attempted to directly or indirectly influence the abstainer's personal network, e.g. by helping the abstainer influence others in their personal network to quit. Personal networks exert powerful effects on initiating and maintaining smoking behavior, and can facilitate maintaining abstinence or trigger relapse. A "help others" intervention that seeks to increase the abstainer's ability to influence smokers in their personal network to quit - thereby creating a social environment more supportive of long-term abstinence - may have a beneficial effect on relapse. The Helpers Stay Quit intervention encourages abstainers to reinforce their own abstinence through helping others quit, and to proactively influence their personal network to be more conducive to long-term smoking abstinence. Helpers Stay Quit teaches abstainers how to encourage other tobacco users to quit and avoid relapse through a non-confrontational "helping conversation" that encourages quitting and use of evidence-based cessation aids (e.g. Quitlines, cessation medications) without confrontation and nagging. The investigator hypothesizes that Quitline abstainers exposed to Helpers Stay Quit will have higher 30-day and 7-day point prevalence abstinence than those receiving Quitline follow-up usual care, and that the effect of Helpers Stay Quit may be mediated by personal network characteristics. To test this hypothesis, the investigator proposes a pragmatic randomized controlled trial with embedded mixed-methods personal network study to assess the effect of Helpers Stay Quit training on proportion and duration of abstainers' abstinence over time, and on abstainer's personal network interactions related to smoking and smoking cessation. Metrics derived from the personal network study will be used for mediational analyses of overall, and gender-based effects of Helpers Stay Quit on smoking relapse.

03

Conditions studied

  • Smoking
  • Cigarette Smoking

Browse trials for

Keywords

  • Smoking cessation
  • Relapse prevention
04

In context

Cigarette Smoking Reclassified

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

This study's enrollment of 940 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.

Browse Cigarette Smoking studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.

Compared within Cigarette Smoking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Smoking. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Abstinent from smoking for between 14 and 60 days
  • Primary tobacco use is cigarettes
  • Has access to Internet via computer or mobile device
  • Self-described proficiency with English
  • Willing and able to send/receive weekly text messages using personal mobile phone plan
  • Will allow Quitline to share their client data with research team
  • Willing to complete online surveys at baseline, 3-, 6-, 9- and 12 months
  • Willing to self-collect dried blood spot and send back to research team
  • If assigned to Helpers Stay Quit condition, willing to complete training within 14 days
  • If selected, willing to participate in qualitative interview
  • Willing to forego any other training for tobacco cessation intervention/support (i.e., to become a cessation counselor/facilitator or support person, e.g., 'quit buddy') for the duration of their study enrollment

Exclusion criteria

Exclusion Criteria:

  • Any prior exposure to Helpers training or other cessation training in the previous 2 years
06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
940 participants (actual)

Study arms

  • Experimental
    Helpers Stay Quit Training

    Research participants randomized to the experimental arm will receive the on-line Helpers Stay Quit training which provides training on how to help others quit smoking.

    Behavioral: Helpers Stay Quit Training

  • No intervention
    Usual Care

    Research participants randomized to the arm without intervention will receive Quitline usual care. They will be contacted for assessment of abstinence at 7 months after enrollment in services. If the participant has relapsed, the Quitline will attempt to re-engage the participant in cessation services (telephone and/or web-based).

Interventions

  • BehavioralHelpers Stay Quit Training

    The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step "helping conversation". The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot "make" anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting.

07

What researchers measure

Primary outcomes

  1. 7-day and 30-day abstinence from using combustible tobacco at 6 months post-randomization

    Participants report the number of days (if any) they smoked combustible tobacco within the specified timeframe.

    Time frame: Self-reported data collected at 6 months post-randomization

  2. 7-day and 30-day abstinence from using combustible tobacco at 12 months post-randomization

    Participants report the number of days (if any) they smoked combustible tobacco within the specified timeframe.

    Time frame: Self-reported data collected at 12 months post-randomization

Secondary outcomes

  1. 7-day and 30-day abstinence from using combustible tobacco at 3 months and 9 months post-randomization

    Participants report the number of days (if any) they smoked combustible tobacco within the specified timeframe.

    Time frame: Self-reported data collected at 3- and 9-months post-randomization

  2. Time to first relapse

    Participants report the number of days (if any) they smoked combustible tobacco within the specified timeframe.

    Time frame: Weekly data collected months 1-6, bi-weekly data collected months 7-12 post-randomization

  3. Number, timing, and duration of relapses

    Participants report the number of days (if any) they smoked combustible tobacco within the specified timeframe.

    Time frame: Weekly data collected months 1-6, bi-weekly data collected months 7-12 post-randomization

  4. Number of helping conversations offered

    Participants report the number of helping conversations (if any) offered within the specified timeframe.

    Time frame: Weekly data collected months 1-6; bi-weekly data collected months 7-12; data collected at 3-, 6-, 9-, and 12-months post-randomization

  5. Biochemical confirmation of abstinence at 6 and 12 months on a subsample

    Participants who report abstinence at 6- and 12-months (and no other exposure to nicotine) receive a dried blood spot kit which is returned and tested for cotinine.

    Time frame: Data collected and 6- and 12-months post-randomization

08

Study locations

1 site
09

References and documents

Publications

  • Muramoto ML, Hopkins A, Bell M, Allen A, Nair U, Connolly TE. Results of a Feasibility Study of Helpers Stay Quit Training for Smoking Relapse Prevention. Nicotine Tob Res. 2021 Mar 19;23(4):711-715. doi: 10.1093/ntr/ntaa176. PubMed 32966558 ↗
  • Muramoto M, Hopkins A, McCarty C, Allen A, Dickinson LM, Connolly T, Spradley J, Ying J. Effect of Helpers Stay Quit Online Training on Preventing Smoking Relapse and Personal Networks: Protocol for a Pragmatic Randomized Controlled Trial and Embedded Mixed Methods Personal Network Study. JMIR Res Protoc. 2026 Jan 27;15:e82140. doi: 10.2196/82140. PubMed 41591931 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 48 months is above that.

Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 8, 2022
StartActual
Dec 12, 2022
Primary completionEst.
Dec 31, 2026was Oct 2026
CompletionEst.
Feb 27, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Dec 31, 2026
Nov 18, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41591931 ↗
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41591931 ↗
    Primary completion Oct 31, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05641974
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Dec 12, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 27, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Myra Muramoto, MD, MPH
principal investigator · University of Colorado School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion